A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012-12 (EDALINE) study.
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
/ pharmacokinetics
Biphenyl Compounds
/ administration & dosage
Carcinoma, Ductal, Breast
/ drug therapy
Docetaxel
/ administration & dosage
Female
Humans
Maximum Tolerated Dose
Middle Aged
Prognosis
Pyridines
/ administration & dosage
Smoothened Receptor
/ antagonists & inhibitors
Tissue Distribution
Triple Negative Breast Neoplasms
/ drug therapy
Hedgehog
Triple negative
advanced breast cancer
docetaxel
hormone receptor and HER2 negative
sonidegib
Journal
Investigational new drugs
ISSN: 1573-0646
Titre abrégé: Invest New Drugs
Pays: United States
ID NLM: 8309330
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
05
04
2018
accepted:
24
05
2018
pubmed:
28
6
2018
medline:
22
1
2020
entrez:
28
6
2018
Statut:
ppublish
Résumé
Up-regulation of the Hedgehog (Hh) pathway is implicated in the genesis of a wide range of tumors including triple negative breast cancer (TNBC). Sonidegib is a potent and selective oral inhibitor of Smo, a key component of the Hh signaling pathway. We designed a phase I clinical study to explore the combination of sonidegib plus docetaxel (fixed dose at 75 mg/m
Identifiants
pubmed: 29948356
doi: 10.1007/s10637-018-0614-9
pii: 10.1007/s10637-018-0614-9
doi:
Substances chimiques
Biphenyl Compounds
0
Pyridines
0
SMO protein, human
0
Smoothened Receptor
0
sonidegib
0RLU3VTK5M
Docetaxel
15H5577CQD
Banques de données
ClinicalTrials.gov
['NCT02027376']
Types de publication
Clinical Trial, Phase I
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
98-108Références
Cancer Med. 2016 Oct;5(10):2989-3006
pubmed: 27539549
Drug Des Devel Ther. 2015 Aug 05;9:4303-18
pubmed: 26273192
Eur J Dermatol. 2016 Oct 1;26(5):427-443
pubmed: 27550571
Expert Opin Ther Pat. 2016;26(1):1-20
pubmed: 26651178
Ther Adv Med Oncol. 2016 Sep;8(5):375-82
pubmed: 27583029
Onco Targets Ther. 2016 Sep 14;9:5671-5678
pubmed: 27695345
Am J Cancer Res. 2016 Sep 01;6(9):1864-1872
pubmed: 27725895
Clin Cancer Res. 2014 Apr 1;20(7):1900-9
pubmed: 24523439
Oncol Lett. 2016 Sep;12(3):1753-1762
pubmed: 27602109
Cancer Res. 2006 Jun 15;66(12):6063-71
pubmed: 16778178
Invest New Drugs. 2017 Dec;35(6):766-772
pubmed: 28317088
Br J Cancer. 2005 Aug 8;93(3):293-301
pubmed: 16052223
Cancer Res. 2009 Jun 1;69(11):4810-7
pubmed: 19458072
Mol Cancer Ther. 2012 Jul;11(7):1587-97
pubmed: 22553355
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Expert Opin Pharmacother. 2016 Oct;17(14):1963-8
pubmed: 27538055
Curr Med Chem. 2017;24(19):2033-2058
pubmed: 28302010
Cancer. 2015 Jan 1;121(1):8-16
pubmed: 25043972
Oncotarget. 2017 Mar 28;8(13):22218-22234
pubmed: 28108739
Cancer Res. 2004 Sep 1;64(17):6071-4
pubmed: 15342389
Cancer Chemother Pharmacol. 2016 Apr;77(4):745-55
pubmed: 26898300
J Clin Oncol. 2013 Nov 1;31(31):3997-4013
pubmed: 24101045
Breast Cancer. 2017 Jan;24(1):63-68
pubmed: 26754092
J Clin Oncol. 2010 Jun 1;28(16):2784-95
pubmed: 20404251